An Audit of Hypophosphatemia after Intravenous Iron Therapy

Choice of High-Dose Intravenous Iron Preparation Determines Hypophosphatemia Risk

BACKGROUND Ferric carboxymaltose (FCM) and iron isomaltoside 1000 (IIM) are increasingly used because they allow correction of severe iron deficiency in a single infusion. A transient decrease in serum phosphate concentrations is a frequent side effect of FCM. AIM To characterize this adverse event and search for its predictors in a gastroenterology clinic patient cohort. METHODS Electronic...

Intravenous Iron Administration and Hypophosphatemia in Clinical Practice

Introduction. Parenteral iron formulations are frequently used to correct iron deficiency anemia (IDA) and iron deficiency (ID). Intravenous formulation efficacy on ferritin and hemoglobin level improvement is greater than that of oral formulations while they are associated with lower gastrointestinal side effects. Ferric carboxymaltose- (FCM-) related hypophosphatemia is frequent and appears w...

Intravenous Iron Therapy with Saccharated Iron Oxide

Ferumoxytol as an intravenous iron replacement therapy in hemodialysis patients.

BACKGROUND AND OBJECTIVES Intravenous iron is a key component of anemia management for chronic kidney disease (CKD). Ferumoxytol is a unique intravenous iron product that can be administered as a rapid injection in doses up to 510 mg. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS This was a randomized, open-label, controlled, multicenter Phase 3 trial to evaluate the safety and efficacy of in...

Intravenous iron therapy restores functional iron deficiency induced by infliximab.

BACKGROUND AND AIMS Infliximab (IFX) and iron sucrose (FeS) are of high value in inflammatory bowel disease (IBD). We aimed to assess the relative role of both therapies in IBD related anaemia and their safety when used in combination. METHODS IBD patients with anaemia receiving a first series of FeS infusions in addition to IFX were prospectively followed. We investigated serum kinetics of e...